Hope is fading fast for torcetrapibBMJ 2007; 334 doi: https://doi.org/10.1136/bmj.39170.502581.80 (Published 05 April 2007) Cite this as: BMJ 2007;334:716
Drugs that increase serum concentrations of high density lipoprotein should theoretically help prevent cardiovascular events such as heart attack. But hope is fading fast for the new drug torcetrapib, which increases concentrations of “good” cholesterol by inhibiting cholesterol ester transfer …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial